All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The virtual AML Hub Satellite Symposium at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) brought together an international panel of experts to discuss how measurable residual disease (MRD) impacts outcome of stem cell transplantation in AML, now and in the future. Professor Adriano Venditti, University of Rome Tor Vergata, Rome, IT, presented the topic ‘Does current evidence support the use of MRD-guided treatment before transplant in patients with AML?’
Apart from being a predictor of outcomes in AML, MRD assessment prior to stem cell transplantation is emerging as an important indicator for therapeutic decision making. Professor Adriano Venditti discusses the results of ongoing clinical trials using an MRD-guided treatment approach and highlights the benefits of stem cell transplantation even in MRD-positive patients, especially those in a specific risk group.
Welcome to the AML Hub Satellite Symposium.
Please take a moment to complete the survey and answer the following question to help us gauge your current understanding of the use of MRD-guided treatment before transplant in patients with AML.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox